# Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT

> **NCT00147563** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 34 (—)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Eplerenone

## Key facts

- **NCT ID:** NCT00147563
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 34 (—)
- **Last updated:** 2008-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147563, "Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00147563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*